Psychopharmacology

, Volume 62, Issue 1, pp 67–69 | Cite as

Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy

  • J. J. Balsara
  • J. H. Jadhav
  • A. G. Chandorkar
Original Investigations

Abstract

Pretreatment with quipazine, a serotonin agonist, and clomipramine, a selective serotonin neuronal uptake blocker, was found to potentiate the cataleptic effect of haloperidol in a dose-dependent manner in rats. Pretreatment with methysergide, a serotonin antagonist, reduced the cataleptic effect of haloperidol. The results indicate that the cataleptic effect of neuroleptics depends on the balance between the dopaminergic and serotonergic systems, and that the serotonergic system exerts an inhibitory influence on the dopaminergic system.

Key words

Quipazine Clomiprimine Methysergide Haloperidol Catalepsy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chase, T. N., Murphy, D. L.: Serotonin and central nervous system function. In: Annual review of pharmacology, vol 13. H. W. Elliot, R. Okun, and R. George, eds., pp. 181–197. California: Annual Reviews Inc. 1973Google Scholar
  2. Costall, B., naylor, R. J.: Stereotyped and circling behavior induced by dopaminergic agonists after lesions of the mid brain raphe nuclei. Eur. J. Pharmacol. 29, 206–222 (1974a)Google Scholar
  3. Costall, B., Naylor, R. J.: Mesolimbic involvement with behavioural effects indicating antipsychotic activity. Eur. J. Pharmacol. 27, 46–58 (1974b)Google Scholar
  4. Franz, D. N.: Drugs for Parkinson's disease; centrally acting muscle relaxants. In: The pharmacological basis of therapeutics, L. S. Goodman and A. Gilman, eds., pp. 227–244. New York: Macmillan Publishing Co., Inc. 1975Google Scholar
  5. Hamon, M., Bourgoin, S., Enjaber, A., Bockaert, J., Hery, F., Ternaux, J. P., Glowinski, J.: The effects of quipazine on 5-HT metabolism in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 294, 99–108 (1976)Google Scholar
  6. Hong, E., Sancilio, L. F., Vargas, R., Pardo, E. G.: Similarities between the pharmacological actions of quipazine and serotonin. Eur. J. Pharmacol. 6, 274–280 (1969)Google Scholar
  7. Kostowski, W., Gumulka, W., Czlonkowski, A.: Reduced cataleptogenic effects of some neuroleptics in rats with lesioned mid brain raphe and treated with p-chlorophenylalanine. Brain Res. 48, 443–446 (1972)Google Scholar
  8. Malec, D., Langwinski, R., Kruszewska, A.: The role of 5-HT in the mechanism of amphetamine action. Pol. J. Pharmacol. Pharm. 27, 155–160 (1975)Google Scholar
  9. Mattysse, S.: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc. 32, 200–205 (1973)Google Scholar
  10. Medon, P. J., Leeling, J. L., Phillips, B. M.: Influence of quipazine, a potential antiparkinsonian agent, on the uptake of 3H-dopamine and 3H-serotonin into rat striatal tissue in vitro. Life Sci. 13, 685–691 (1973)Google Scholar
  11. Parizek, J., Hassler, R., Bak, I. J.: Light and electron microscopic autoradiography of substantia nigra of rat after intraventricular administration of tritium labeled norepinephrine, serotonin, dopamine and the precursors. Z. Zellforsch. Mikrosk. Anat 115, 137–148 (1971)Google Scholar
  12. Pollin, W., Cardon, P. V., Kety, S.: Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 133, 104–105 (1961)Google Scholar
  13. Rodriguez, R., Rojas-Ramirez, J. A., Drucker-Colin, R. R.: Serotonin-like actions of quipazine on the central nervous system. Eur. J. Pharmacol. 24, 164–171 (1973)Google Scholar
  14. Ross, S. B., Renyi, A. L.: Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3H-noradrenaline and 14C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain. Acta Pharmacol. Toxicol. 36, 382–394 (1975)Google Scholar
  15. Ross, S. B., Renyi, A. L., Ogren, S. O.: Inhibition of the uptake of noradrenaline and 5-hydroxytryptamine by chlorphentermine and chlorimipramine. Eur. J. Pharmacol. 17, 107–112 (1972)Google Scholar
  16. Snyder, S. H., Banerjee, S. P., Yamamura, H. I., Greenberg, D.: Drugs, neurotransmitters, and schizophrenia. Science 184, 1243–1253 (1974)Google Scholar
  17. Wyatt, R. J., Vaughan, T., Galanter, M., Green, R., Kaplan, J.: Behavioral changes of chronic schizophrenic patients given l-5-hydroxytryptophan. Science 177, 1124–1126 (1972)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • J. J. Balsara
    • 1
  • J. H. Jadhav
    • 1
  • A. G. Chandorkar
    • 1
  1. 1.Department of PharmacologyV. M. Medical CollegeSolapur (Maharashtra)India

Personalised recommendations